ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Chongqing Precision Biotech Co., Ltd clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 51 studies whose lead sponsor is Chongqing Precision Biotech Co., Ltd. 37 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 4, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Compare Chongqing Precision Biotech with AstraZeneca and Jiangsu HengRui Medicine →

Pipeline: 11 programs

Each counted once: 11 with a study Chongqing Precision Biotech Co., Ltd leads registered in the last two years.

  • Phase 1
  • Phase 2

5 from the earlier phases, besides the phase-3 view.

Program
CEA-targeted CAR-T cellsPhase 2 · 4 live · Stomach Neoplasms · primary completion Dec 2026☆ Track
CD19 CAR-T cellsPhase 2 · 2 live · Leukemia, Lymphocytic, Chronic, B-Cell☆ Track
Anti-CD70 CAR-expressing T LymphocytesPhase 1 · 6 live · Neoplasm Metastasis · primary completion Dec 2026☆ Track
Targeted CEA CAR-TPhase 1 · 4 live · Lung Neoplasms · primary completion Dec 2026☆ Track
MC-1-50Phase 1 · 3 live · Lupus Erythematosus, Systemic · primary completion Nov 2027☆ Track

6 more — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Chongqing Precision Biotech Co., Ltd’s own registered studies; Chongqing Precision Biotech Co., Ltd’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Chongqing Precision Biotech Co., Ltd’s studies test, most open studies first — 5 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

11 of Chongqing Precision Biotech Co., Ltd’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 7D
  3. J’27
  4. F
  5. 1M
  6. A
  7. M
  8. 1J
  9. 1J
  10. A
  11. S
  12. O
  13. 1N

Add all 11 to your calendar (.ics) → With an account.

All 51 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now3773%Recruiting 35 · Not yet recruiting 2
  • Completed48%
  • Stopped early24%Withdrawn 1 · Suspended 1
  • Status unknown or other816%

Phase

Where

Over the years

  1. 19
  2. 20
  3. 21
  4. 22
  5. 23
  6. 24
  7. 925
  8. 626

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Chongqing Precision Biotech Co., Ltd.

  • Chongqing Precision Biotech Co., Ltd
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    51 studies

Studies

Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →